Epalrestat

Synonym(s):(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid

CAS NO.：82159-09-9
Empirical Formula: C15H13NO3S2
Molecular Weight: 319.4
MDL number: MFCD00865484
EINECS: 675-018-0
SAFETY DATA SHEET (SDS)
Update Date: 2024-11-15 19:19:13

What is Epalrestat?

Description

Epalrestat is the second aldose reductase inhibitor to be introduced worldwide and the first to be launched in Japan. The compound is indicated for the treatment of diabetic neuropathy. It is also being investigated for diabetic retinopathy and nephropathy.

Chemical properties

Red Solid

Originator

Ono (Japan)

The Uses of Epalrestat

Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM

The Uses of Epalrestat

An aldose reductase inhibitor. It is used in treatment of diabetic neuropathy.

The Uses of Epalrestat

Epalrestat has been used as an aldose reductase inhibitor:

in the dahomey larvae diet fed forDrosophila
for non-irradiated and X-ray irradiated human aldose reductase
to test its protective effect in mice with bleomycin-induced pulmonary fibrosis

What are the applications of Application

Epalrestat is an aldose reductase inhibitor

Definition

ChEBI: A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.

brand name

Kinedak

Biochem/physiol Actions

Epalrestat inhibits Aldose Reductase (AR) involved in the rate limiting step in the conversion of glucose to sorbitol under hyperglycemic conditions. Aldose reductase has been the target of multiple clinical investigatons to treat diabetic neuropathy and retinopathy. Epalrestat is an approved drug in Japan and India, used for the treatment of diabetic neuropathy.

References

1) Kikkawa?et al. (1983)?Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235), on peripheral nerve disorders in streptozotocin diabetic rats; Diabetologica,?24?290 2) Terashima?et al. (1984)?Effects of a new aldose reductase inhibitor on various tissues in vitro; J. Pharmacol. Exp. Ther.,?229?226 3) Ramirez and Borja (2008)?Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy; Pharmacotherapy,?28?646

Properties of Epalrestat

Melting point:	210-217 C
Boiling point:	516.8±60.0 °C(Predicted)
Density	1.43±0.1 g/cm3(Predicted)
storage temp.	-20°C
solubility	DMSO: soluble5mg/mL, clear (warmed)
pka	3.62±0.10(Predicted)
form	powder
color	yellow to orange
Merck	14,3605
Stability:	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months.
InChI	InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-

Safety information for Epalrestat

Signal word	Danger
Pictogram(s)	Skull and Crossbones Acute Toxicity GHS06
GHS Hazard Statements	H300:Acute toxicity,oral
Precautionary Statement Codes	P264:Wash hands thoroughly after handling. P264:Wash skin thouroughly after handling. P270:Do not eat, drink or smoke when using this product. P405:Store locked up. P501:Dispose of contents/container to..…